Prostate cancer (PCa) ranks as the second most common cancer in men.26 The conventional diagnostic approach is based on determination of the highly variable prostate specific antigen (PSA).27 Nevertheless, novel biomarkers and therapy targets are investigated for diagnosis and treatment, including potential biomarkers present in sEVs.13,28,29. This evidence concerns the gene KLK3 and cancer.